Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-15T08:11:00.163Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of Nosocomial Vancomycin-Resistant Enterococcal Bacteremia on Mortality, Length of Stay, and Costs

Published online by Cambridge University Press:  02 January 2015

Xiaoyan Song ,
Arjun Srinivasan ,
David Plaut  and
Trish M. Perl
Xiaoyan Song*
Affiliation:
Department of Hospital Epidemiology and Infection Control, The Johns Hopkins School of Medicine, Baltimore, Maryland
Arjun Srinivasan
Affiliation:
Department of Hospital Epidemiology and Infection Control, The Johns Hopkins School of Medicine, Baltimore, Maryland Department of Antibiotic Management, The Johns Hopkins School of Medicine, Baltimore, Maryland
David Plaut
Affiliation:
Department of Casemix Information Management, The Johns Hopkins School of Medicine, Baltimore, Maryland
Trish M. Perl
Affiliation:
Department of Hospital Epidemiology and Infection Control, The Johns Hopkins School of Medicine, Baltimore, Maryland Division of Infectious Diseases, The Johns Hopkins School of Medicine, Baltimore, Maryland Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
*
Department of Hospital Epidemiology and Infection Control, The Johns Hopkins Hospital, Carnegie 288, 600 N. Wolfe Street, Baltimore, MD 21287
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To determine the impact of vancomycin-resistant enterococcal bacteremia on patient outcomes and costs by assessing mortality, excess length of stay, and charges attributable to it.

Design:

A population-based, matched, historical cohort study.

Setting:

A 1,025-bed, university-based teaching facility and referral hospital.

Patients:

Two hundred seventy-seven vancomycin-resistant enterococcal bacteremia case-patients and 277 matched control-patients identified between 1993 and 2000.

Results:

The crude mortality rate was 50.2% and 19.9% for case-patients and control-patients, respectively, yielding a mortality rate of 30.3% attributable to vancomycin-resistant enterococcal bacteremia. The excess length of hospital stay attributable to vancomycin-resistant enterococcal bacteremia was 17 days, of which 12 days were spent in intensive care units. On average, $77,558 in extra charges was attributable to each vancomycin-resistant enterococcal bacteremia. To adjust for severity of illness, 159 pairs of case-patients and control-patients, who had the same severity of illness (All Patient Refined-Diagnosis Related Group complexity level), were further analyzed. When patients were stratified by severity of illness, the crude mortality rate was 50.3% among case-patients compared with 27.7% among control-patients, accounting for an attributable mortality rate of 22.6%. Attributable excess length of stay and charges were 17 days and $81,208, respectively.

Conclusion:

Vancomycin-resistant enterococcal bacteremia contributes significantly to excess mortality and economic loss, once severity of illness is considered. Efforts to prevent these infections will likely be cost-effective.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 24 , Issue 4 , April 2003 , pp. 251 - 256
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Newell, KA, Millis, JM, Arnow, PM, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation 1998;65:439–442.Google Scholar
2.Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin: United States, 1989-1993. MMWR 1993;42:597–599.Google Scholar
3.Shay, DK, Maloney, SA, Montecalvo, M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995;172:993–1000.Google Scholar
4.Linden, PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998;104:1S–2S.Google Scholar
5.Linden, PK, Miller, CB. Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen. Diagn Microbiol Infect Dis 1999;33:113–120.CrossRefGoogle ScholarPubMed
6.Bhavnani, SM, Drake, JA, Forrest, A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000;36:145–158.CrossRefGoogle ScholarPubMed
7.Edmond, MB, Ober, JF, Dawson, JD, Weinbaum, DL, Wenzel, RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234–1239.CrossRefGoogle ScholarPubMed
8.Garner, JS, Jarvis, WR, Emori, TG, Horan, TC, Hughes, JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.CrossRefGoogle ScholarPubMed
9.3M Health Information Systems. All Patient Refined-Diagnosis Related Groups Définitions Manual, version 15.0. St. Paul, MN: 3M Health Information Systems; 1998.Google Scholar
10.Lucas, GM, Lechtzin, N, Puryear, DW, Yau, LL, Flexner, CW, Moore, RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis 1998;26:1127–1133.CrossRefGoogle ScholarPubMed
11.Beltrami, EM, Singer, DA, Fish, L, et al. Risk factors for acquisition of vancomycin-resistant enterococci among patients on a renal ward during a community hospital outbreak. Am J Infect Control 2000;28:282–285.Google Scholar
12.Brown, AR, Amyes, SG, Paton, R, et al. Epidemiology and control of van-comycin-resistant enterococci (VRE) in a renal unit. J Hosp infect 1998;40:115–124.CrossRefGoogle Scholar
13.Mainous, MR, Lipsett, PA, O'Brien, M. Enterococcal bacteremia in the surgical intensive care unit: does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group. Arch Surg 1997;132:76–81.CrossRefGoogle Scholar
14.Lautenbach, E, Bilker, WB, Brennan, PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318–323.CrossRefGoogle ScholarPubMed
15.Haley, RW. Measuring the costs of nosocomial infections: methods for estimating economic burden for the hospital. Am J Med 1991;16:145S–151S.Google Scholar
16.Bhorade, SM, Christenson, J, Pohlman, AS, Arnow, PM, Hall, JB. The incidence of and clinical variables associated with vancomycin-resistant enterococcal colonization in mechanically ventilated patients. Chest 1999;115:1085–1091.Google Scholar
17.Stosor, V, Peterson, LR, Postelnick, M, Noskin, GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158:522–527.Google Scholar
18.Austin, DJ, Bonten, MJ, Weinstein, RA, Slaughter, S, Anderson, RM. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci USA 1999;96:6908–6913.Google Scholar
19.Dembek, ZF, Kellerman, SE, Ganley, L, et al. Reporting of vancomycin-resistant enterococci in Connecticut: implementation and validation of a state-based surveillance system. Infect Control Hosp Epidemiol 1999;20:671–675.CrossRefGoogle ScholarPubMed
20.Srinivasan, A, Song, XS, Brower, R, Perl, MT. Gowns and gloves precautions versus gloves alone in preventing transmissions of vancomycin resistant enterococci (VRE) in an ICU. Presented at the 38th Annual Meeting of the Infectious Diseases Society of America; September 710, 2000; New Orleans, LA.Google Scholar
21.Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HIC-PAC). MMWR 1995;44(RR12):1–13.Google Scholar
22.Morgan, AS, Brennan, PJ, Fishman, NO. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Ann Pharmacother 1997;31:970–973.Google Scholar